Drug Trial Radar · NCT05834348
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,279
Actual
Start
Jun 23, 2023
Primary completion
Jan 23, 2024
Study completion Jan 23, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 28, 2023
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. Metastasis is when the cancer cells spread to other parts of the body. This study includes patient's data from the database who: * Are 18 years of age or older. * Are confirmed to have metastatic non-small cell lung cancer between 01 January 2009 and 31 December 2022. The study is based on data collection from 3 national health registries: * The Cancer Registry of Norway (CRN), * The Norwegian Patient Registry (NPR), * The Norwegian Drug Registry (NDR). Data from these registries will be linked at an individual patient level to create a single, unified dataset. The information collected includes: Diagnosis, cancer stage at diagnosis, date of diagnosis, birth year, type of medicinal treatment, date of treatment start and end, treating hospital, age, gender, etc.
Conditions
- Non-Small Cell Lung Cancer
Interventions
lorlatinibDrug
As provided in real world practice
crizotinibDrug
As provided in real world practice
brigatinibDrug
As provided in real world practice
ceritinibDrug
As provided in real world practice
alectinibDrug
As provided in real world practice
atezolizumabDrug
As provided in real world practice
bevacizumabDrug
As provided in real world practice
paclitaxelDrug
As provided in real world practice
carboplatinDrug
As provided in real world practice
docetaxelDrug
As provided in real world practice
erlotinibDrug
As provided in real world practice
gefitinibDrug
As provided in real world practice
afatinibDrug
As provided in real world practice
dacomitinibDrug
As provided in real world practice
osimertinibDrug
As provided in real world practice
pembrolizumabDrug
As provided in real world practice
nivolumabDrug
As provided in real world practice
entrectinibDrug
As provided in real world practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Treatment of Anti-cancer DrugsTime frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
- Number of Participants Classified According to Treatments of Anti-cancer DrugsTime frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
- Number of Participants Classified According to Treatment Lines of Anti-cancer DrugsTime frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
- Overall Survival (OS)Time frame: From treatment initiation (1-Jan-2015) to date of death (until 31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Norway
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.